KR20220023340A - mRNA 제형 - Google Patents

mRNA 제형 Download PDF

Info

Publication number
KR20220023340A
KR20220023340A KR1020217038364A KR20217038364A KR20220023340A KR 20220023340 A KR20220023340 A KR 20220023340A KR 1020217038364 A KR1020217038364 A KR 1020217038364A KR 20217038364 A KR20217038364 A KR 20217038364A KR 20220023340 A KR20220023340 A KR 20220023340A
Authority
KR
South Korea
Prior art keywords
mrna
pseudouridine
combination
thio
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217038364A
Other languages
English (en)
Korean (ko)
Inventor
스테파안 디 코커
상느 비버스
피터 토미
Original Assignee
이더알엔에이 이뮤노테라피스 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이더알엔에이 이뮤노테라피스 엔브이 filed Critical 이더알엔에이 이뮤노테라피스 엔브이
Publication of KR20220023340A publication Critical patent/KR20220023340A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217038364A 2019-04-26 2020-04-24 mRNA 제형 Pending KR20220023340A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
EP19171323.9 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (1)

Publication Number Publication Date
KR20220023340A true KR20220023340A (ko) 2022-03-02

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038364A Pending KR20220023340A (ko) 2019-04-26 2020-04-24 mRNA 제형

Country Status (12)

Country Link
US (1) US20220362360A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958893A1 (cg-RX-API-DMAC7.html)
JP (1) JP7650001B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220023340A (cg-RX-API-DMAC7.html)
CN (1) CN114096272B (cg-RX-API-DMAC7.html)
AU (1) AU2020263948B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021262A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138011A1 (cg-RX-API-DMAC7.html)
IL (1) IL287560B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021013018A (cg-RX-API-DMAC7.html)
SG (1) SG11202111720TA (cg-RX-API-DMAC7.html)
WO (1) WO2020216911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー mRNAワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Also Published As

Publication number Publication date
BR112021021262A2 (pt) 2021-12-21
SG11202111720TA (en) 2021-11-29
AU2020263948B2 (en) 2026-06-25
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
JP7650001B2 (ja) 2025-03-24
IL287560B2 (en) 2026-02-01
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
IL287560A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7650001B2 (ja) mRNA製剤
Kottke et al. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer
Franzusoff et al. Yeasts encoding tumour antigens in cancer immunotherapy
TW202003032A (zh) 包含s t i n g 促效劑之胞外囊泡
JP2019515900A (ja) がんを処置するためのToll様レセプター9アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
US20250041394A1 (en) Immunostimulatory mrna compositions and uses thereof
KR20240134324A (ko) mRNA 치료 조성물
US20240102047A1 (en) An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide
CN116113422A (zh) 免疫细胞的mRNA转染
KR20170100033A (ko) 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법
AU2021347807A9 (en) Improved methods and compositions for expression of nucleic acids in cells
KR20220094221A (ko) 종양의 치료를 위한 il-12 디스플레잉 엑소좀과 조합된 sting 효능제 포함 엑소좀
JP6273290B2 (ja) 疾患の処置のための同種異系のオートファゴソーム強化組成物
Su et al. Immune‐check blocking combination multiple cytokines shown curative potential in mice tumor model
JP2026512425A (ja) 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
US20200038496A1 (en) Novel vegfr-2 targeting immunotherapy approach
WO2021074648A1 (en) Vector for cancer treatment
JP2023502925A (ja) 生体内遺伝子治療のためのポリマー封入ウイルスベクター
HK40068420A (en) Mrna formulation
HK40068420B (en) Mrna formulation
Jeon Role of toll-like receptor agonists as cancer vaccine adjuvants
JP2025508829A (ja) 負に帯電した粒子による固形腫瘍の治療
CN122057015A (zh) 基于肿瘤特异性抗原的细胞治疗制剂及其在实体瘤中的应用
Pulakkat et al. Immunogene Therapy in Cancer
Parikh et al. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000